Rigel Pharmaceuticals, Incorporated

Other

Torch Therapeutics

Rigel, Inc.

Rogel Pharmaceuticals, Inc.

Donald G Payan

Rajinder Paul Singh

Hui Li

Somasekhar Bhamidipati

Jeffrey Clough

Ankush Argade

Sacha Holland

Catherine Sylvain

Holger Keim

Alexander B Rossi

Susan Molineaux

Esteban Masuda

Yasumichi Hitoshi

Dane A Goff

Kin Tso

David Carroll

Todd M Kinsella

Simon Shaw

Rao Kolluri

Yan Chen

Thilo J Heckrodt

Rose Yen

Jing Zhang

Matthew Duncton

Salvador Alvarez

Pingyu Ding

Marina Gelman

Vanessa Taylor

Ryan Kelley

Mary Shen

Simon Yu

Sasha J Holland

Ying Luo

Betty Huang

Taisei Kinoshita

James B Lorens

Jianing Huang

Sylvia Braselmann

Stephanie Yung

Tarikere Gururaja

Joseph Fisher

Elliot B Grossbard

Rongxian Ding

Xian Wu

Dane Goff

Garry P Nolan

Arvinder Sran

Brian Wong

John Yudhistir Ramphal

Ramesh Bhatt

Henry Lu

Sarkiz D Issakani

Haoran Zhao

Joseph R Fisher

Bruce A Wang

Shihai Gu

Kunbin Qu

Nan Lin

Kristen Baltgalvis

Lyuben Tsvetkov

Ziang Xu

Yanmei Lu

Hitoshi Yasumichi

Sacha J Holland

Elliott B Grossbard

Compounds and embodiments of a method for treating and/or preventing autoimmune diseases are disclosed. The method includes administering to a subject having an autoimmune disease, such as an inflammatory bowel disease, a therapeutically effective amount of a compound according to formula I wherein X and Y independently are O or NR; each Ris independently H or C-Calkyl; ring A is aryl; each Rindependently is H, alkyl, alkoxy, amide, cyano, halo, haloalkyl, hydroxyalkyl, heteroalkyl, heterocyclyl, sulfonyl, sulfonamide, or two Rgroups, taken together with the atom or atoms to which they are attached, combine to form a 4-10 membered ring system; p is 0, 1, 2, 3, or 4; Rand Rindependently are H or C-Calkyl; and Ris halo, cyano, or C-Calkyl.

Compounds and method for treating autoimmune diseases

This invention describes the design of bispecific antibodies that function as conditionally effective therapeutics by binding to a functionally silent epitope on one component of a targeted signaling complex and simultaneously binding to a second protein, whose expression or accessibility is cell- or disease environment-specific, and whose antibody-driven proximity to the signaling complex leads to an alteration of signal transduction.

Method of using a bispecific antibody to conditionally inhibit a receptor signaling complex

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

2,4-pyrimidinediamine compounds and their uses

Disclosed are substituted pyridine compounds as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure wherein E, J, T, the ring system denoted by 'B', T, R, R, w and x are as described herein. In certain embodiments, a compound disclosed herein activates the AMPK pathway, and can be used to treat metabolism-related disorders and conditions.

AMPK-activating heterocyclic compounds and methods for using the same

The invention described herein comprises compounds and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds inhibit signaling by a member of the TGF-&#x3b2; superfamily such as Nodal or Activin.

2,3-Disubstituted pyridine compounds as TGF-&#x3b2; inhibitors and methods of use

This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Protein kinase C inhibitors and uses thereof

The invention described herein comprises compounds of formula (IV) and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds (IV) inhibit signaling by a member of the TGF-&#x3b2; superfamily such as Nodal or Activin. 

2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use

Disclosed are sulfonamidoquinoline compounds, as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein R, R, Rand Rare as described herein. In certain embodiments, a compound disclosed herein inhibits ubiquitination, and can be used to treat disease by blocking the degradation of tumor suppressors.

Ubiquitination inhibitors

Growing community of inventors

Hillsborough, CA, United States of America

Donald G Payan